Tag Archives: bispecific myeloid cell engager

Sanofi Completes $600 Million Acquisition of DR-0201 to Enhance Immunology Pipeline and Advance Autoimmune Disease Treatments

(IN BRIEF) Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline. This bispecific myeloid cell engager, which has shown promising results in B-cell depletion, may offer potential breakthroughs in autoimmune diseases, … Read the full press release